###begin article-title 0
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3
###end article-title 0
###begin p 1
###xml 33 55 33 55 <email xmlns:xlink="http://www.w3.org/1999/xlink">S.Tangye@garvan.org.au</email>
###xml 76 99 76 99 <email xmlns:xlink="http://www.w3.org/1999/xlink">matthew.cook@anu.edu.au</email>
CORRESPONDENCE Stuart G. Tangye: S.Tangye@garvan.org.au OR Matthew C. Cook: matthew.cook@anu.edu.au
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 177 198 177 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 203 219 203 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 540 545 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 1080 1089 1076 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 1094 1105 1090 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 177 198 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 203 219 <span type="species:ncbi:5476">Candida albicans</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 946 954 <span type="species:ncbi:9606">patients</span>
###xml 1080 1089 <span type="species:ncbi:1280">S. aureus</span>
###xml 1094 1105 <span type="species:ncbi:5476">C. albicans</span>
Hyper-immunoglobulin E syndrome (HIES) is a primary immune deficiency characterized by abnormal and devastating susceptibility to a narrow spectrum of infections, most commonly Staphylococcus aureus and Candida albicans. Recent investigations have identified mutations in STAT3 in the majority of HIES patients studied. Despite the identification of the genetic cause of HIES, the mechanisms underlying the pathological features of this disease remain to be elucidated. Here, we demonstrate a failure of CD4+ T cells harboring heterozygous STAT3 mutations to generate interleukin 17-secreting (i.e., T helper [Th]17) cells in vivo and in vitro due to a failure to express sufficient levels of the Th17-specific transcriptional regulator retinoid-related orphan receptor gammat. Because Th17 cells are enriched for cells with specificities against fungal antigens, our results may explain the pattern of infection susceptibility characteristic of patients with HIES. Furthermore, they underscore the importance of Th17 responses in normal host defense against the common pathogens S. aureus and C. albicans.
###end p 3
###begin p 4
S.G. Tangye and M.C. Cook contributed equally to this paper.
###end p 4
###begin p 5
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 458 459 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 665 666 665 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 742 743 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 745 746 742 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 748 749 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 761 762 758 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 764 765 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 767 768 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 975 976 964 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 977 979 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1133 1134 1122 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 1136 1137 1125 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 1492 1493 1475 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1523 1525 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1527 1529 1510 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 579 584 <span type="species:ncbi:9606">human</span>
###xml 655 661 <span type="species:ncbi:10090">murine</span>
###xml 1155 1159 <span type="species:ncbi:10090">mice</span>
###xml 1218 1223 <span type="species:ncbi:9606">human</span>
###xml 1477 1482 <span type="species:ncbi:9606">human</span>
###xml 1642 1647 <span type="species:ncbi:9606">human</span>
Appropriate immune responses to particular pathogens are orchestrated by distinct T cell populations with relatively stable cytokine expression profiles that differentiate during antigen-specific clonal proliferation. Such differentiation of CD4+ T cells is determined by signals provided by components of the innate immune system and is subsequently stabilized by induction and repression of key transcriptional regulators (1). Recently, IL-17-producing CD4+ T cells (Th17) have been identified as the key mediators of inflammation and tissue damage in several animal models of human diseases (for review see references 1 and 2). The commitment of naive murine CD4+ T cells to the Th17 lineage requires exposure to TGF-beta and either IL-6 (1, 3, 4) or IL-21 (2, 5, 6). These cytokines act in a STAT3-dependent manner to induce expression of retinoid-related orphan receptor gammat (RORgammat), the critical transcription factor necessary for the development of Th17 cells (7-10), which subsequently induces a set of effector molecules, including IL-17, IL-21, IL-22, and IL-23R plus several chemokines and other defense molecules (1, 2). In contrast to mice, much less is known about the requirements for generating human Th17 cells. Indeed, although there is consensus that TGF-beta is not required for this process, and is actually inhibitory, controversy exists as to whether IL-6 or IL-23, in combination with IL-1beta, is the predominant cue that mediates commitment of human naive CD4+ T cells to the Th17 lineage (11, 12). Given these differences, it is important to dissect further the molecular requirements for the development of human Th17 cells.
###end p 5
###begin p 6
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 612 618 <span type="species:ncbi:9606">humans</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
Although inappropriate Th17 differentiation helps explain autoimmune disease and inflammation, the physiological function of Th17 cells appears to lie in host protection against specific pathogens (1, 2). Based on the anatomical distribution of Th17 cells and the capacity of IL-17 to regulate granulopoiesis, neutrophil chemotaxis, and production of microbiocidal peptides by epithelium in mice, it is likely that Th17 cells confer immunity to pathogens on mucosal and possibly other epithelial surfaces (8, 13). For instance, Th17 cells appear to have a predominant role in antifungal immune responses in both humans and mice (14-16).
###end p 6
###begin p 7
###xml 173 194 173 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 199 215 199 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 317 326 317 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 843 848 843 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1134 1141 1134 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 1146 1155 1146 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 1223 1225 1223 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1299 1310 1299 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1334 1339 1334 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 1401 1403 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1405 1407 1405 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1518 1519 1518 1519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1529 1530 1529 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1532 1533 1532 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1535 1537 1535 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1561 1566 1561 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 173 194 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 199 215 <span type="species:ncbi:5476">Candida albicans</span>
###xml 226 234 <span type="species:ncbi:9606">Patients</span>
###xml 317 326 <span type="species:ncbi:1280">S. aureus</span>
###xml 695 703 <span type="species:ncbi:9606">Patients</span>
###xml 894 902 <span type="species:ncbi:9606">patients</span>
###xml 1146 1155 <span type="species:ncbi:1280">S. aureus</span>
###xml 1232 1237 <span type="species:ncbi:9606">human</span>
###xml 1299 1310 <span type="species:ncbi:5476">C. albicans</span>
###xml 1437 1443 <span type="species:ncbi:10090">murine</span>
###xml 1473 1477 <span type="species:ncbi:10090">mice</span>
###xml 1614 1620 <span type="species:ncbi:9606">humans</span>
Hyper-IgE (HIES), or Job's, syndrome (OMIM 147060) is a primary immune deficiency characterized by abnormal susceptibility to a narrow spectrum of infections, most commonly Staphylococcus aureus and Candida albicans (17, 18). Patients with HIES often suffer from mucocutaneous candidiasis, whereas local and invasive S. aureus infections lead to persistent eczematoid eruptions, recurrent skin and joint abscesses, and lung damage. In addition to recurrent tissue-destructive infections, the HIES phenotype includes coarse facies, osteopenia resulting in fractures after relatively minor trauma, scoliosis and craniosynostosis, delayed shedding of the primary dentition, and short stature (18). Patients also exhibit dramatic increases in serum IgE (>10 times normal) (17, 18). Recently, heterozygous missense mutations and short deletions in STAT3 have been identified in the majority of HIES patients studied (19, 20). Despite the identification of the genetic cause of HIES, the mechanisms underlying the pathological features of this disease remain to be elucidated. Based on the observations that (a) defects in immunity to both Candida and S. aureus are prominent features of HIES, especially at epithelial surfaces (18), (b) human Th17 cells have specificities for fungal antigens, including C. albicans (14), (c) heterozygous STAT3 mutations are responsible for HIES in the majority of cases (19, 20), and (d) the development of murine Th17 cells is compromised in mice lacking expression of STAT3 in their CD4+ T cells (7, 9, 10), we hypothesized that STAT3 mutations conferred specific susceptibility in humans with HIES to infection via an inability to generate Th17 cells.
###end p 7
###begin title 8
RESULTS AND DISCUSSION
###end title 8
###begin title 9
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Characteristics of HIES patients and STAT3 mutations
###end title 9
###begin p 10
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 299 308 299 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 487 494 487 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 103 110 <span type="species:ncbi:9606">patient</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 299 308 <span type="species:ncbi:1280">S. aureus</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
Five unrelated patients with HIES were identified according to their clinical phenotype (Table I). One patient (HIES4) had a family history of HIES (her mother had succumbed to infection but was not available for this analysis). All patients had a history of recurrent infection, including invasive S. aureus and mucocutaneous candidiasis. In addition, all patients had features typical of the autosomal-dominant form of HIES, with abnormalities of the skeleton, teeth, and soft tissue (Table I). Phenotype scores ranged from 26 to 71 according to the proposed HIES score (an age-sensitive scoring with HIES being most likely in patients with a score >40) (21).
###end p 10
###begin p 11
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Characteristics of HIES patients
###end p 11
###begin p 12
DNABD, DNA binding domain; SH2, src homology 2 domain.
###end p 12
###begin p 13
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 338 345 338 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 492 494 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 496 498 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 682 684 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 686 688 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 690 692 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 35 42 <span type="species:ncbi:9606">patient</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
Genomic DNA was isolated from each patient, and exons 13-21 of STAT3, which encompass the DNA binding and SH2 domains, were sequenced. Heterozygous missense mutations were identified in all five patients. Four harbored mutations in the DNA binding domain (R382Q [n = 2], V432M, and H437P) and one had a mutation in the SH2 domain (Q644P; Table I). The R382 residue is a common site of mutation, accounting for approximately30% (18/58) of reported HIES genotypes, with R382Q in 8 of those 18 (19, 20). Most of the mutations we identified have previously been demonstrated to impair the ability of STAT3 to translocate to the nucleus and activate transcription of STAT3 target genes (19, 20, 22).
###end p 13
###begin title 14
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
Heterozygous STAT3 mutations abrogate the generation of Th17 cells in vivo
###end title 14
###begin p 15
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 402 403 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
To test the hypothesis that missense mutations in STAT3 would confer a defect in human Th17 cell differentiation, CD4+ T cells from HIES patients were examined and compared with those from matched normal controls. Flow cytometric analysis revealed normal development of CD4+ T cells, with comparable proportions of naive (CD45RA+ CD27+), central memory (CD45RA- CD27+) and effector memory (CD45RA- CD27-) cells in HIES patients and healthy controls (not depicted).
###end p 15
###begin p 16
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 439 440 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 495 510 495 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and C</xref>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 664 679 664 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 698 699 698 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 748 749 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 782 797 782 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 884 885 884 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 906 907 906 907 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1004 1005 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1047 1055 1047 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 1173 1174 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1184 1192 1184 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 772 780 <span type="species:ncbi:9606">patients</span>
###xml 1037 1045 <span type="species:ncbi:9606">patients</span>
###xml 1071 1078 <span type="species:ncbi:9606">patient</span>
To investigate whether Th17 cells were present within the circulating T cell population of HIES patients in vivo, total CD4+ T cells were stimulated in vitro with anti-CD3 mAb, anti-CD28 mAb, and IL-2 for 4-5 d. The proportion of Th17 cells within the population was assessed by intracellular staining for IL-17 after restimulation with PMA and ionomycin. A small but consistent population of IL-17-expressing cells was detected in the CD4+ T cells examined for all healthy donors (1.2%; n = 5; Fig. 1, A and C). In contrast, there was a significant reduction in IL-17+ cells from the cultures of stimulated STAT3 mutant HIES CD4+ T cells (0.44%; n = 5; P < 0.05; Fig. 1, B and C). Indeed, no IL-17+ cells could be detected after stimulation of CD4+ T cells from two HIES patients (Fig. 1, B and C). These findings were corroborated by examination of IL-17 secretion by stimulated CD4+ T cells. Control CD4+ T cells secreted abundant quantities of IL-17, whereas IL-17 was undetectable in cultures of CD4+ T cells from four of five HIES patients (Fig. 1 D). In the fifth patient, the concentration of IL-17 was >20-fold lower than the average amount produced by control CD4+ T cells (Fig. 1 D).
###end p 16
###begin p 17
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIES patients have a defect in the generation of IL-17&#8211;producing CD4<sup>+</sup> T cells in vivo.</bold>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 278 279 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 674 675 674 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 769 770 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 987 988 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 192 199 <span type="species:ncbi:9606">patient</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 589 596 <span type="species:ncbi:9606">patient</span>
###xml 722 729 <span type="species:ncbi:9606">patient</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
HIES patients have a defect in the generation of IL-17-producing CD4+ T cells in vivo. Intracellular expression of IL-17A and IL-2 in purified CD4+ T cells from a healthy donor (A) and a HIES patient (B) activated for 5 d (see Materials and methods). (C) The frequency of IL-17A+ cells, determined by intracellular cytokine expression, and (D) IL-17A secretion by CD4+ T cells from five healthy donors and five HIES patients that had been stimulated with anti-CD3 mAb, anti-CD28 mAb, and IL-2 for 4-5 d, as determined by ELISA. Each symbol represents the value from an individual donor or patient, and the line represents the mean. (E) Time course of IL-17A secretion by CD4+ T cells isolated from a normal donor and HIES patient. Similar results were obtained when CD4+ T cells from all HIES patients were examined over a culture period that continued for up to 11 d. (F and G) Expression of IL-22 mRNA (relative to housekeeping genes; F) and secreted protein (G) by normal and HIES CD4+ T cells was determined after 2 and 5 d, respectively, of stimulation with CD3/CD28/IL-2. *, P < 0.05; **, P < 0.01.
###end p 17
###begin p 18
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 226 227 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 341 349 341 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 464 472 464 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 606 614 606 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
###xml 658 659 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 819 820 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 830 838 830 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 G</xref>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
To exclude a difference in the rate of IL-17 secretion by HIES CD4+ T cells, production of IL-17 by activated CD4+ T cells from healthy donors and HIES patients was measured over an 11-d time course. In cultures of healthy CD4+ T cells, IL-17 was first detected after 4 d, peaked on days 5-6, and remained stable or declined at later times (Fig. 1 E). In contrast, no IL-17 was detected in the supernatants of HIES CD4+ T cells at any of the time points examined (Fig. 1 E). We also assessed expression of IL-22, a Th17-derived cytokine thought to be important in epithelial immunity (23, 24). IL-22 mRNA (Fig. 1 F) was significantly reduced in activated CD4+ T cells from HIES patients compared with healthy controls (P < 0.01). Furthermore, there was a complete absence of IL-22 secretion in cultures of activated CD4+ T cells (Fig. 1 G). This finding demonstrates that production of both IL-17 and IL-22 by in vivo-generated Th17 cells is dependent on functional STAT3 protein and confirm that IL-22 is a signature Th17 cytokine.
###end p 18
###begin title 19
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
HIES CD4+ T cells fail to up-regulate expression of RORgammat, the Th17 lineage-specific transcriptional regulator
###end title 19
###begin p 20
###xml 58 59 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 144 145 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 147 148 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 150 152 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 234 235 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 318 319 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 353 354 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 364 372 352 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Differentiation of Th17 cells is determined by RORgammat (8). Because induction of this key transcription factor in mice is regulated by STAT3 (7, 9, 10), we tested for a possible defect in the expression of RORgammat mRNA in HIES CD4+ T cells. We found a fourfold reduction of RORgammat message in stimulated HIES CD4+ T cells compared with control CD4+ T cells (Fig. 2 A).
###end p 20
###begin p 21
###xml 0 45 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Deficiency of ROR&#947;t mRNA in HIES patients</bold>
###xml 83 84 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Deficiency of RORgammat mRNA in HIES patients. (A) RORgammat mRNA expression in CD4+ cells activated for 2 d with CD3/CD28/IL-2 in five HIES patients and five normal controls. (B) RORgammat mRNA expression after 2 d of culture is proportional to the number of Th17 cells as determined by intracellular cytokine expression after 4-5 d.
###end p 21
###begin p 22
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 192 197 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 380 381 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">,</italic>
###xml 451 459 439 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
Given that STAT3 monomers must undergo homodimerization to be functional (25), a fourfold reduction in expression of RORgammat is consistent with the prediction that a single mutant allele of STAT3 would reduce functional STAT3 homodimers by 75%. In our cohort of patients, the quantity of RORgammat mRNA correlated with the number of Th17 cells induced after stimulation in vitro, which would be expected if RORgammat specifies Th17 differentiation (Fig. 2 B).
###end p 22
###begin title 23
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 158 160 158 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FH</sub>
HIES CD4+ T cells can proliferate, produce Th1- and Th2-type cytokines, and undergo in vivo differentiation to T regulatory (T reg) and T follicular helper (TFH) cell phenotypes
###end title 23
###begin p 24
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 230 238 230 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 314 325 310 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B&#8211;E</xref>
###xml 339 347 331 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 F</xref>
###xml 366 381 358 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, G and I</xref>
###xml 425 426 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 471 479 459 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 794 795 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 873 874 845 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 884 892 856 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 H</xref>
###xml 997 998 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1082 1083 1054 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1093 1095 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 1245 1246 1213 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1275 1283 1243 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 I</xref>
###xml 1359 1374 1327 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, D and E</xref>
###xml 1400 1401 1368 1369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1515 1526 1483 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B&#8211;D</xref>
###xml 1569 1570 1537 1538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1574 1576 1542 1544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1581 1583 1549 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 1592 1594 1560 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1601 1603 1569 1571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FH</sub>
###xml 1625 1626 1593 1594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1631 1632 1599 1600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1641 1643 1609 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 1714 1729 1682 1697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, J and K</xref>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
###xml 1036 1040 <span type="species:ncbi:10090">mice</span>
###xml 1265 1273 <span type="species:ncbi:9606">patients</span>
###xml 1704 1712 <span type="species:ncbi:9606">patients</span>
The defect in IL-17 secretion and Th17 cell differentiation by HIES CD4+ T cells did not appear to result from a general defect in lymphocyte activation. HIES CD4+ T cells proliferated to a similar extent as control counterparts (Fig. 3 A). Furthermore, there was no significant defect in production of IFN-gamma (Fig. 3, B-E), TNF-alpha (Fig. 3 F), IL-4, or IL-13 (Fig. 3, G and I). IFN-gamma secretion by activated HIES CD4+ T cells was reduced compared with controls (Fig. 3 E), but this reduction did not reach statistical significance, and there was no deficiency of IFN-gamma-producing cells when assessed by flow cytometry after restimulation with PMA/ionomycin. Interestingly, there was a consistent and significant reduction (approximately3.5-fold; P < 0.01) in IL-10 production by CD4+ T cells from all HIES patients examined relative to production by control CD4+ T cells (Fig. 3 H). This probably reflects a specific intrinsic requirement for STAT3 in IL-10 production by activated CD4+ T cells, as recently demonstrated in mice that specifically lack STAT3 in their CD4+ T cells (26). Despite reductions in secretion of IFN-gamma and IL-10, measurable amounts of these cytokines were clearly present in the cultures of activated CD4+ T cells from HIES patients (Fig. 3 I), which contrasts the complete deficit in IL-17 production by these cells (Fig. 1, D and E). Interestingly, HIES CD4+ T cells consistently gave rise to an increased frequency of cells expressing IL-2 compared with normal controls (Fig. 3, B-D). Furthermore, T reg cells (defined as CD4+CD25hiCD127lo cells) (27) and TFH cells (defined as CD4+CXCR5+ cells) (28) were found to be present in normal numbers ex vivo in HIES patients (Fig. 3, J and K).
###end p 24
###begin p 25
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 111 113 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FH</sub>
###xml 0 134 0 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD4<sup>+</sup> T cells from HIES patients undergo normal proliferation and differentiation into Th1-, Th2-, T reg&#8211;, and T<sub>FH</sub>-type effector cells.</bold>
###xml 223 224 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 344 345 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 556 557 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 753 754 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 828 829 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 911 913 895 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 918 920 902 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 948 950 932 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FH</sub>
###xml 1243 1244 1227 1228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1249 1250 1233 1234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 521 528 <span type="species:ncbi:9606">patient</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
###xml 1091 1098 <span type="species:ncbi:9606">patient</span>
###xml 1139 1146 <span type="species:ncbi:9606">patient</span>
###xml 1284 1292 <span type="species:ncbi:9606">patients</span>
###xml 1398 1405 <span type="species:ncbi:9606">patient</span>
CD4+ T cells from HIES patients undergo normal proliferation and differentiation into Th1-, Th2-, T reg-, and TFH-type effector cells. (A) CFSE profiles of normal (outline black histogram) and HIES (solid red histogram) CD4+ T cells after stimulation with CD3/CD28 mAb and IL-2 for 5 d. (B) Intracellular expression of IFN-gamma and IL-2 in CD4+ T cells purified from normal donors and HIES patients after activation for 4-5 d with CD3/CD28/IL-2. The FACS plots in B are representative of one normal control and one HIES patient. (C and D) Frequency of CD4+ T cells from normal controls and HIES patients that expressed IL-2 (C) or IFN-gamma (D). (E-I) Secretion of IFN-gamma (E), TNF-alpha (F), IL-4 (G), IL-10 (H), and IL-13 (I) by normal and HIES CD4+ T cells stimulated with anti-CD3/CD28 mAb and IL-2 for 5 d. (J and K) CD4+ T cells were labeled with either (J) CD25 and CD127 to identify T reg cells (CD25hiCD127lo) or (K) CXCR5 to identify TFH cells, as indicated by the gated populations. The values represent the frequency of gated cells and are from one healthy donor and one HIES patient and are representative of at least four patient and control samples. (L) PBMCs were labeled with anti-CD4 and CCR6 mAb, and the frequency of CD4+ CCR6+ cells in healthy donors and HIES patients was enumerated. For all graphs (E-I and L), each symbol represents the value from an individual donor or patient, and the line represents the mean. *, P < 0.05; **, P < 0.01; ns, not significant.
###end p 25
###begin p 26
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 202 203 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 281 282 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 307 315 295 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 L</xref>
###xml 342 343 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 393 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 L</xref>
###xml 491 492 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 496 497 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 584 586 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 872 877 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 1082 1084 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 481 486 <span type="species:ncbi:9606">human</span>
###xml 950 958 <span type="species:ncbi:9606">patients</span>
###xml 1047 1055 <span type="species:ncbi:9606">patients</span>
It has been recently reported that Th17 cells express the chemokine receptor CCR6 (14, 29). Because IL-17-producing cells were absent from the CD4+ T cell compartment of HIES patients, we enumerated CD4+ CCR6+ T cells in peripheral blood. In healthy donors, approximately20% of CD4+ T cells expressed CCR6 (Fig. 3 L). In contrast, <10% of CD4+ T cells expressed CCR6 in HIES patients (Fig. 3 L), consistent with the suggestion that CCR6 identifies Th17 cells. Furthermore, because human CCR6+ CD4+ T cells have been shown to secrete both IL-17 and IFN-gamma under some circumstances (29), deficiency of this subset might account for the reduction in IFN-gamma sometimes observed in HIES. It is important to emphasize that previous assessments of IFN-gamma production in HIES are inconsistent, which could also be due to heterogeneity of HIES cohorts before genotyping for STAT3 became available. Indeed, recent evidence indicates that some HIES-like patients with normal STAT3 exhibit deficiencies of IFN-gamma production, whereas STAT3-deficient patients have no IFN-gamma defect (30).
###end p 26
###begin title 27
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Naive CD4+ T cells fail to differentiate into Th17 cells in vitro
###end title 27
###begin p 28
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 226 227 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 408 409 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 513 515 513 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FH</sub>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 768 769 768 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 858 859 858 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1024 1025 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1226 1227 1223 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1469 1477 1463 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 1615 1616 1606 1607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1728 1736 1719 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 1780 1781 1771 1772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1871 1879 1862 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 2074 2075 2053 2054 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2146 2157 2125 2136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A&#8211;E</xref>
###xml 2190 2191 2169 2170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2222 2223 2201 2202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2326 2327 2305 2306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
Human naive CD4+ T cells do not produce IL-17 when stimulated through CD3 and CD28 (11, 12). Thus, the detection of IL-17 in the cultures of total CD4+ T cells activated with anti-CD3/CD28 mAb reflects production by memory CD4+ T cells that have differentiated to the Th17 lineage in vivo. The requirement of STAT3 in CD4+ T cell differentiation in vivo appears to be specific to the Th17 lineage because CD4+ T cells from HIES patients could give rise to effector cells with features of Th1-, Th2-, T reg-, and TFH-type cells in vivo. Because STAT3 is ubiquitously expressed and functions downstream of numerous cytokine receptors (25), it was possible that the inability to generate Th17 cells in vivo was a consequence of a requirement for STAT3 function in non-CD4+ T cells, for instance antigen-presenting cells, that instruct the differentiation of CD4+ T cells. It was therefore important to demonstrate an intrinsic requirement of STAT3 in naive CD4+ T cells for their commitment to the Th17 lineage. Thus, naive CD4+ T cells were sort-purified and then cultured with beads coated with anti-CD2, anti-CD3, and anti-CD28 together with various combinations of IL-1beta, IL-6, and IL-23. Secretion of IL-17A by normal CD4+ T cells was not detected until the cells had been subjected to three rounds of stimulation in vitro with anti-CD2, anti-CD3 plus anti-CD28 mAb-coated beads, and either IL-1beta plus IL-6 or IL-23, with each stimulation period lasting 4-5 d (Fig. 4 A). The combination of IL-1beta plus IL-6 was approximately fivefold more effective at inducing production of IL-17A by activated naive CD4+ T cells than IL-23, and there was a further two- to threefold increase in the presence of all three cytokines (Fig. 4 A). In complete contrast, when naive HIES CD4+ T cells were cultured under the same optimized conditions they failed to produce IL-17A (Fig. 4 A). Although these culture conditions induced IL-17A, we were unable to detect IL-17A-expressing cells by intracellular staining (not depicted). Because only approximately1% of total activated CD4+ T cells expressed IL-17A, yet secreted up to 10,000 pg/ml IL-17A (see Fig. 1, A-E), our inability to detect IL-17A+ cells in cultures of naive CD4+ T cells most likely reflects the fact that these cells secreted 10-20-fold less IL-17A than memory CD4+ T cells.
###end p 28
###begin p 29
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 150 0 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Naive CD4<sup>+</sup> T cells from HIES patients fail to differentiate to the Th17 lineage in vitro in response to the STAT3-activating cytokines IL-6 and IL-23.</bold>
###xml 160 161 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 248 255 <span type="species:ncbi:9606">patient</span>
Naive CD4+ T cells from HIES patients fail to differentiate to the Th17 lineage in vitro in response to the STAT3-activating cytokines IL-6 and IL-23. Naive CD4+ T cells isolated from a normal donor (blacksquare, square, filled, square) and a HIES patient (black triangle, triangle up) were cultured with anti-CD2, anti-CD3, and anti-CD28 mAb-coated beads either alone (CD3) or in the presence of IL-1beta plus IL-6 (IL-1beta+IL-6), IL-23 (IL-23), or all three cytokines (IL-1beta +IL-6+IL-23). The cells were harvested after 5 d and then recultured under the same conditions for another two rounds of stimulation. (A) IL-17A secretion was determined after either 3 d (blacksquare, square, filled, black triangle; total time of culture, 12 d) or 6 d of the third round of restimulation (square, triangle up; total time of culture, 15 d). (B) Expression of RORgammat mRNA in cells stimulated for 5 d (blacksquare, square, filled, black triangle) or 15 d (square, triangle up) was determined by quantitative PCR.
###end p 29
###begin p 30
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 340 341 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 390 398 379 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 539 547 524 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 671 673 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 686 688 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 780 782 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 928 929 913 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 955 961 940 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
###xml 913 918 <span type="species:ncbi:9606">human</span>
Consistent with the defect in differentiation of naive HIES CD4+ T cells into Th17 cells in the presence of IL-1beta, IL-6, and IL-23, we demonstrated a defect in induction of RORgammat in T cells in response to each of these stimuli. The induction of RORgammat mRNA was >10-fold greater in IL-23-containing culture conditions in normal CD4+ T cells compared with those from HIES patients (Fig. 4 B). Interestingly, induction of RORgammat expression appeared to be absolutely dependent on IL-23, whereas there was a lesser effect of IL-6 (Fig. 4 B). These findings recapitulate the in vivo Th17 differentiation defect in HIES and are consistent with the ability of IL-6 (25) and IL-23 (31) to both activate STAT3. Furthermore, although IL-23 can also activate STAT-1, -4, and -5 (31), it would appear that IL-23-induced activation of STAT3 plays a predominant role in amplifying the generation of Th17 cells from human naive CD4+ T cells induced by IL-6 (Fig. 2).
###end p 30
###begin p 31
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 469 476 469 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 486 495 486 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 676 683 676 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 784 791 784 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 793 795 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1075 1077 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 1207 1208 1207 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1282 1284 1282 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1363 1370 1363 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 1555 1556 1555 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1558 1566 1558 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">albicans</italic>
###xml 1568 1570 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1609 1611 1609 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1634 1635 1634 1635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1762 1773 1762 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 1778 1787 1778 1787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 1940 1961 1940 1961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Klebsiella pneumoniae</italic>
###xml 1971 1973 1971 1973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 486 495 <span type="species:ncbi:1280">S. aureus</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 744 749 <span type="species:ncbi:9606">human</span>
###xml 1227 1235 <span type="species:ncbi:9606">patients</span>
###xml 1532 1536 <span type="species:ncbi:10090">mice</span>
###xml 1555 1566 <span type="species:ncbi:5476">C. albicans</span>
###xml 1654 1662 <span type="species:ncbi:9606">patients</span>
###xml 1762 1773 <span type="species:ncbi:5476">C. albicans</span>
###xml 1778 1787 <span type="species:ncbi:1280">S. aureus</span>
###xml 1940 1961 <span type="species:ncbi:573">Klebsiella pneumoniae</span>
###xml 1965 1969 <span type="species:ncbi:10090">mice</span>
Our findings identify a fundamental defect in Th17 differentiation in HIES. Thus, enumeration of IL-17 production by activated CD4+ T cells, coupled with measuring the frequency of CCR6+CD4+ T cells, emerges as a relatively quick and simple procedure that could be used to screen patients suspected of having HIES due to inactivating mutations in STAT3. In addition, our findings also point to a crucial role for Th17 cells in the normal host response. Infections with Candida spp. and S. aureus, the most prevalent etiological agents in the infections encountered in patients with HIES, are also important pathogens in other clinical settings. Mechanisms for defense against Candida and other fungal infections have been contentious. Although human Th17 cells respond selectively to Candida (14), other evidence suggests that production of IL-17 and IL-23 increases susceptibility to fungal infection in vivo (32). Furthermore, a role for T reg cells has been proposed, whereby down-regulation of Th17-mediated inflammation is necessary to prevent fungal-induced pathology (33). However, we did not detect a deficiency of T reg cells, at least by cell surface phenotype, in HIES. Our observations using CD4+ T cells from HIES patients supports the data of Acosta-Rodriguez et al. (14) that Th17 cells play a crucial role in coordinating the host defense against Candida. This most likely reflects a direct function of IL-17 produced by Th17 cells, as demonstrated by the requirement of the IL-17R in protective immune responses in mice to infection with C. albicans (15). Recent evidence from Milner et al. (30) demonstrates that CD4+ T cells from HIES patients fail to differentiate in vitro into IL-17-producing effector cells in response to stimulation with C. albicans and S. aureus. Deficiency of IL-17 is not necessarily the only mechanism of immunodeficiency in HIES because IL-22 has been shown to contribute to protection against Klebsiella pneumoniae in mice (23), and we show that IL-22 production is also reduced significantly in HIES.
###end p 31
###begin p 32
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
Although our findings help to explain the spectrum of infections in HIES, other aspects of the complex phenotype require elucidation. A similar cell-intrinsic effect of STAT3 acting within chondrocytes or osteoblasts may explain some of the skeletal defects as evidenced in mice with a conditional hematopoietic cell-specific disruption of the STAT3 gene (34). Craniosynostosis and midline abnormalities, for example, can result from defects in the transcription factor TWIST, which is induced by STAT3 (35, 36). The mechanism of the HIES component of the phenotype is also likely to be complex because STAT3 operates intrinsically in B cells and is activated in response to many regulatory cytokines, including IL-6, IL-10, and IL-21, and, as shown here, T helper signals are also disrupted.
###end p 32
###begin p 33
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 433 440 433 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 388 395 <span type="species:ncbi:9606">patient</span>
Finally, illumination of the aspects of the HIES phenotype that arise as a consequence of Th17 deficiency may sound a note of caution when considering IL-17 antagonism in autoimmune and inflammatory diseases (9, 10). On the other hand, administration of IL-17 or IL-22 may represent a therapeutic approach to controlling specific pathogen infections in HIES patients, as well as in other patient groups who exhibit susceptibility to Candida.
###end p 33
###begin title 34
MATERIALS AND METHODS
###end title 34
###begin title 35
Reagents.
###end title 35
###begin p 36
###xml 387 392 <span type="species:ncbi:9606">human</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
###xml 507 512 <span type="species:ncbi:9606">human</span>
Allophycocyanin-conjugated anti-IFN-gamma mAb was purchased from Invitrogen, and FITC-anti-IL-17A was purchased from eBioscience. Alexa 647-anti-CXCR5, allophycocyanin-anti-CD25, FITC-anti-CD45RA, PE-conjugated anti-IL-2 and anti-CD27, PE-Cy7-anti-CD4, and PE-anti-CCR6 were purchased from BD Biosciences. ECD-conjugated anti-CD4 and PE-anti-CD127 were from Beckman Coulter. Recombinant human IL-2 (rIL-2) was purchased from Endogen, recombinant human IL-1beta and IL-6 were from PeproTech, and recombinant human IL-23 was purchased from eBioscience. Anti-CD28 mAb was purchased from BD Biosciences, anti-CD3 mAb (Spv-T3b) was provided by H. Spits (NKI, Amsterdam, Netherlands), and anti-CD2-, anti-CD3-, and anti-CD28-coated beads were purchased from Miltenyi Biotec (T cell activation/expansion kit). PMA, calcium ionophore (ionomycin), brefeldin A, and saponin were all purchased from Sigma-Aldrich. CFSE was purchased from Invitrogen.
###end p 36
###begin title 37
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients.
###end title 37
###begin p 38
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
Five normal donors and five patients with the clinical diagnosis of HIES were recruited from Immunology Clinics in Canberra and Sydney, Australia. The cited HIES score (21) is age sensitive; therefore, the low score in the 7-yr-old patient did not argue against testing her for mutations in STAT3. All studies were approved by the institutional human research ethics committees (Canberra and Westmead hospitals).
###end p 38
###begin title 39
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Identification of STAT3 mutations in HIES patients.
###end title 39
###begin p 40
Genomic DNA was isolated from saliva samples, and exons 13-21 encompassing the DNA binding and SH2 domains were amplified by PCR and sequenced (ABI Prism 7700). The following primers were used: exons 12-14, TAGTTTAAAGAAATGCCCAGGAGCACAGAG and TTGGCCTAAGTGACTTTTTGGAATAACTACAGC; exon 15, TGCTGTGCTGCTTAGACTGG and CCCCTGTACGTAGCCTCTCCA; exon 16, GAGATGCGGGTGAAGAGATT and CTTGTTTAGATGAGGGATGGTG; exon 17, AGTGCCCCCTCCTTTTAGTT and CCCAAATGAACAGCCCTATG; exons 18 and 19, TGCACACACACAACAGTGC and TCTGTCCAACCTACCCTTCG; exon 20, GGACAGAGTGTGCACAGATGTAA and CACTGGAGCAAGCAAAACAA; and exon 21, GCTTAAGTCTTTTCCCCTTCG and GCATTTGCCTATCTATCCTCCA.
###end p 40
###begin title 41
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD4+ T cell isolation, phenotyping, and cell culture.
###end title 41
###begin p 42
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 363 365 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 371 372 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 410 412 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 544 545 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 585 586 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 590 591 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 599 601 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 950 951 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 962 964 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 966 968 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Whole blood was collected from normal donors and HIES patients, and PBMCs were prepared by centrifugation using Ficoll-Paque. CD4+ T cells were then isolated by positive selection using the CD4-DYNA beads. Purified CD4+ T cells were cultured in 24-well plates (2 x 105 cells/ml) with immobilized 5 mug/ml anti-CD3 mAb, 750 ng/ml anti-CD28 mAb, and 20 U/ml rIL-2 (37). CD4+ T cells were also labeled with CFSE (37), and their proliferation was determined after 5 d of in vitro culture. For in vitro differentiation to the Th17 lineage, naive CD4+ T cells were isolated by sorting CD45RA+CD27+ cells (37) and then culturing them with anti-CD2-, anti-CD3-, and anti-CD28-coated beads (one bead per five cells), and 20 U/ml rIL-2 alone or in the presence of 20 ng/ml IL-23 only, 10 ng/ml IL-1beta plus 50 ng/ml IL-6, or IL-1beta, IL-6, and IL-23. The cells were harvested every 4-5 d before being washed and recultured under the same conditions at 2 x 105 cells/ml (11, 12).
###end p 42
###begin p 43
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 139 140 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 236 238 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FH</sub>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 322 324 322 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 329 331 329 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 345 346 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
The frequencies of CD4+ T cells that were of a naive, conventional memory, or effector memory phenotype, were determined by enumerating CD4+ T cells that were either CD45RA+CD27+, CD45RA-CD27+, or CD45RA-CD27-, respectively. T reg and TFH cells were quantitated by determining the frequency of CD4+ T cells that had a CD25hiCD127lo (27) or CXCR5+ (28) phenotype, respectively.
###end p 43
###begin title 44
Intracellular cytokine staining and ELISA.
###end title 44
###begin p 45
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 439 441 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 609 614 <span type="species:ncbi:9606">human</span>
###xml 744 749 <span type="species:ncbi:9606">Human</span>
###xml 1196 1207 <span type="species:ncbi:3704">horseradish</span>
After 5 or 6 d of activation with the conditions mentioned above, CD4+ T cells were harvested and restimulated for 6 h with 100 ng/ml PMA and 750 ng/ml ionomycin, with 10 mug/ml brefeldin A added after 2 h. After this time, cells were fixed in 2% formaldehyde (Sigma-Aldrich) and stained for expression of intracellular cytokines (IL-2, IL-17A, and IFN-gamma). All antibody staining and wash steps were performed in 0.5% saponin solution (37). Data were acquired using a FACSCanto or LSRII (BD Biosciences) and analyzed using FlowJo software (Tree Star). IL-17A in culture supernatants was measured using the human IL-17A ELISA Ready-SET-Go kit according to the manufacturer's instructions (eBioscience). IL-22 secretion was measured using the Human IL-22 ELISA Development kit from PeproTech. Secretion of IL-4, IL-10, IL-13, IFN-gamma, and TNF-alpha was determined by ELISA using purified and biotinylated cytokine-specific mAb (IL-4: 8D4-8 and MP4-25D2; IL-10: JES3-12G8 and JES3-9D7; IL-13: PVM13-1 and polyclonal; IFN-gamma: NIB42 and 4S.B3; TNF-alpha: MAb1 and MAb11; from BD Biosciences and eBioscience) as the capture and detection mAbs, respectively, and visualization with streptavidin-horseradish peroxidase and TMB substrate.
###end p 45
###begin title 46
mRNA quantitation.
###end title 46
###begin p 47
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 442 451 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ROR&#947;t</italic>
###xml 503 509 499 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBE2D2</italic>
###xml 568 572 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL22</italic>
###xml 902 909 894 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;Ct</sup>
After 2 d of culture, CD4+ T cells were harvested and washed with PBS. Total RNA was isolated using the QIAGEN RNeasy kit according to the manufacturer's instructions. For quantitative RT-PCR, total RNA was reverse transcribed using oligo-dT according to the Invitrogen protocol. cDNA expression was determined using the ABI Prism 7900 sequence detection system and Syber-green reagents (Applied Biosystems). The following primers were used: RORgammat, TCAGTCATGAGAACACAAATTGA and GCACCCCTCACAGGTGATAA; UBE2D2, TGAAGAGAATCCACAAGGAATTGA and CAACAGGACCTGCTGAACACTG; and IL22, AGGCTCAGCAACAGGCTAAG and TCCTTCAGCTTTTGCACATT. Fluorescence signals were measured over 40 PCR cycles, and the cycle (Ct) at which signals crossed a threshold set within the logarithmic phase was recorded. The Ct for the target gene was subtracted from the Ct for UBE2D2 (DeltaCt). The relative amount of mRNA was calculated as 2DeltaCt.
###end p 47
###begin p 48
We thank Drs. Carola Vinuesa and Elissa Deenick for helpful discussions, Gill Tangye for establishing the cytokine ELISAs, and Karen Fenimore for providing reagents.
###end p 48
###begin p 49
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia. C.S. Ma, G.Y.J. Chew, and S.G. Tangye are the recipients of Research Fellowships awarded by the NHMRC.
###end p 49
###begin p 50
The authors have no conflicting financial interests.
###end p 50

